Spots Global Cancer Trial Database for neoplasms by histologic type
Every month we try and update this database with for neoplasms by histologic type cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| Detection and Characterization of Sessile Serrated Lesions (SSL) of the Right Colon | NCT02861885 | Colorectal Neop... Sessile Serrate... Neoplasms | Chromoendoscopy | 18 Years - | Hospices Civils de Lyon | |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Renal Cell Carcinoma Microenvironment Discovery Project | NCT04005183 | Renal Cell Carc... | 18 Years - | University Health Network, Toronto | ||
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | NCT03495921 | Ewing Sarcoma Ewing Family of... Ewing's Tumor M... Ewing's Sarcoma... Ewing's Tumor R... Rare Diseases Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms, Bone... Neoplasms, Conn... Sarcoma, Ewing Neoplasms | Vigil Irinotecan Temozolomide | 2 Years - | Gradalis, Inc. | |
| A Trial In Patients With Advanced Cancer And Leukemia | NCT00878189 | Neoplasms by Hi... | PF-03084014 | 16 Years - | Pfizer | |
| Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | NCT03114670 | Adult Acute Mye... | CD123CAR-41BB-C... | 18 Years - | Affiliated Hospital to Academy of Military Medical Sciences | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | NCT01995942 | Adenocarcinoma Rectal Diseases Colorectal Neop... Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT01471782 | Acute Lymphobla... | Blinatumomab | - 17 Years | Amgen Research (Munich) GmbH | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | NCT02467270 | Myeloid Leukemi... | Ponatinib | 18 Years - | Takeda | |
| A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | NCT05160168 | Gastrointestina... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... | THE-630 | 18 Years - | Theseus Pharmaceuticals | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | NCT02134262 | Relapsed or Ref... | Cyclophosphamid... Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3 | 20 Years - 70 Years | Jichi Medical University | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients | NCT01579253 | Glioblastoma Nervous System ... Central Nervous... Astrocytoma Glioma Neoplasms, Neur... Neuroectodermal... Neoplasms by Hi... Neoplasms, Nerv... | 18 Years - 75 Years | Ludwig-Maximilians - University of Munich | ||
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | NCT01088815 | Metastatic Panc... | Gemcitabine, na... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) | NCT02112656 | Hepatocellular ... | ThermoDox Dummy infusion | 18 Years - | Imunon | |
| A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | NCT00841191 | Ovarian Neoplas... Pancreatic Neop... Colorectal Neop... Head and Neck N... Lung Neoplasms | CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... CNTO 328; Anti-... | 18 Years - | Centocor, Inc. | |
| A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | NCT04544748 | Carcinoma, Non-... Carcinoma, Rena... Melanoma | GNR-051 | 18 Years - | AO GENERIUM | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Vorasidenib Expanded Access Program | NCT05592743 | Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv... | Vorasidenib | 12 Years - | Servier | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | NCT05147493 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Bortezomib Cyclophosphamid... Dexamethasone Lenalidomide | 18 Years - | Hellenic Society of Hematology | |
| Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture | NCT05440240 | Dupuytren Contr... Dupuytren's Dis... Contracture Joint Diseases Musculoskeletal... Fibroma Neoplasm, Fibro... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Connective Tiss... | Percutaneous ne... Corticosteroid ... Saline injectio... | 45 Years - 99 Years | Regionshospitalet Silkeborg | |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | NCT05297734 | End of Life Cancer | Receive technol... Receive redesig... | 21 Years - | Stanford University | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma | NCT01339975 | Carcinoma Carcinoma Renal... Kidney Neoplasm... Kidney Diseases Chemokines | Biological samp... Biological samp... | 18 Years - | University Hospital, Bordeaux | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Low Rectal Cancer Study (MERCURY II) | NCT02005965 | Adenocarcinoma Adenocarcinoma,... Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neoplasms Neoplasms, Cyst... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Digestive Syste... Gastrointestina... Intestinal Dise... Rectal Diseases | 18 Years - | Royal Marsden NHS Foundation Trust | ||
| A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | NCT00102609 | Soft Tissue Sar... Sarcoma Neoplasms, Conn... Neoplasms by Hi... Neoplasms | Doxorubicin Trabectedin Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NCT02909452 | Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors | Entinostat Pembrolizumab | 18 Years - | Syndax Pharmaceuticals | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | NCT05155215 | Lymphoma Lymphoma, Mantl... Neoplasms by Hi... Neoplasms Lymphoprolifera... | IM19 CAR-T cell... Cyclophosphamid... Fludarabine | 18 Years - | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | NCT05298683 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Pomalidomide Dexamethasone Acetaminophen (... Ranitidine (or ... Diphenhydramine... | 18 Years - | Hellenic Society of Hematology | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | NCT02690545 | Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | NCT02197169 | Glioblastoma or... | Single intratum... Interferon-gamm... | 18 Years - | DNAtrix, Inc. | |
| Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | NCT05186558 | Lymphoma, Large... Neoplasms by Hi... | penpulimab, len... | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| A Trial In Patients With Advanced Cancer And Leukemia | NCT00878189 | Neoplasms by Hi... | PF-03084014 | 16 Years - | Pfizer | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | NCT05153408 | Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ... | BLU-701 osimertinib carboplatin pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia | NCT02627677 | Chronic Phase C... | Ponatinib 30 mg... Ponatinib 15 mg... Nilotinib 400 m... | 18 Years - | Takeda | |
| Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors | NCT01177007 | Liver Neoplasms | TheraSphere, Yt... | 18 Years - | Yale University | |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | NCT03037385 | RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... | pralsetinib (BL... | 18 Years - | Hoffmann-La Roche | |
| Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture | NCT05440240 | Dupuytren Contr... Dupuytren's Dis... Contracture Joint Diseases Musculoskeletal... Fibroma Neoplasm, Fibro... Neoplasms, Conn... Neoplasms, Conn... Neoplasms by Hi... Neoplasms Connective Tiss... | Percutaneous ne... Corticosteroid ... Saline injectio... | 45 Years - 99 Years | Regionshospitalet Silkeborg | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | NCT05252078 | Esophageal Squa... Esophageal Neop... Esophageal Dise... Gastrointestina... Gastrointestina... Digestive Syste... Digestive Syste... Neoplasms by Si... Neoplasms by Hi... Neoplasms, Squa... Carcinoma, Squa... | Anlotinib hydro... TQB2450 | 18 Years - | Jiangxi Provincial Cancer Hospital | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions. | NCT04593407 | Neoplasms, Colo... | Endoscopic muco... Endoscopic subm... | 18 Years - 85 Years | Hospital Universitario 12 de Octubre | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic | ||
| Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT06175780 | Neoplasms Neoplasms by Hi... | KY-0118 KY-0118 KY-0118 | 18 Years - 75 Years | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | NCT01997840 | Multiple Myelom... | ACY-1215 (Ricol... | 18 Years - | Celgene | |
| TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | NCT05233098 | Hepatocellular ... | Technetium-99m ... | 21 Years - | Boston Scientific Corporation | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
